The role of a specialist bridging service. A New Zealand prospective study of 600 patients.
A proposition for the Wellington hospital thrombosis service to manage periprocedure anticoagulation bridging was made after a number of cancellations and key incidents were caused by lack of a consistent management approach. We provided individual bridging assessments, with implementation, communication, and education. The only funded anticoagulants in New Zealand at that time were dabigatran, warfarin, and enoxaparin. On initiation of the bridging service, we prospectively collected data on 600 consecutive patients referred to the periprocedure bridging service between May 2015 and February 2017. We recorded the 30-day major bleeding events, thrombotic events, and related mortality. We followed the patients up for 30 days postprocedure. As part of this process, we ensured optimal transition back to their initial anticoagulant. We found low rates of major bleeding 1.9% and thrombosis 0.8% at day 30 comparable to randomized controlled trials. Of the 222 patients taking dabigatran experienced no major bleeding events. We believe using a specialist coagulation service is optimal to ensure surgery can proceed safely.